COSCIENS Biopharma (CSCI) Competitors $2.84 -0.14 (-4.70%) (As of 02:56 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends CSCI vs. RVPH, VYNE, RLYB, XLO, ANEB, BRNS, OSTX, LUMO, RAPT, and FGENShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Reviva Pharmaceuticals (RVPH), VYNE Therapeutics (VYNE), Rallybio (RLYB), Xilio Therapeutics (XLO), Anebulo Pharmaceuticals (ANEB), Barinthus Biotherapeutics (BRNS), OS Therapies (OSTX), Lumos Pharma (LUMO), RAPT Therapeutics (RAPT), and FibroGen (FGEN). These companies are all part of the "pharmaceutical preparations" industry. COSCIENS Biopharma vs. Reviva Pharmaceuticals VYNE Therapeutics Rallybio Xilio Therapeutics Anebulo Pharmaceuticals Barinthus Biotherapeutics OS Therapies Lumos Pharma RAPT Therapeutics FibroGen COSCIENS Biopharma (NASDAQ:CSCI) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility & risk, CSCI or RVPH? COSCIENS Biopharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Do institutionals and insiders hold more shares of CSCI or RVPH? 0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, CSCI or RVPH? COSCIENS Biopharma has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$4.50M2.37-$16.55M-$11.87-0.24Reviva PharmaceuticalsN/AN/A-$39.26M-$1.11-1.14 Does the MarketBeat Community favor CSCI or RVPH? Reviva Pharmaceuticals received 22 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformCOSCIENS BiopharmaN/AN/AReviva PharmaceuticalsOutperform Votes2288.00% Underperform Votes312.00% Do analysts rate CSCI or RVPH? Reviva Pharmaceuticals has a consensus price target of $15.50, suggesting a potential upside of 1,125.30%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Reviva Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer CSCI or RVPH? In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for COSCIENS Biopharma. COSCIENS Biopharma's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Overall Sentiment COSCIENS Biopharma Neutral Reviva Pharmaceuticals Neutral Is CSCI or RVPH more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. Reviva Pharmaceuticals' return on equity of 0.00% beat COSCIENS Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-428.43% -95.93% -45.66% Reviva Pharmaceuticals N/A N/A -252.53% SummaryReviva Pharmaceuticals beats COSCIENS Biopharma on 11 of the 16 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.68M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-0.245.5695.6214.26Price / Sales2.37371.591,217.1987.73Price / CashN/A52.5939.5936.27Price / Book0.5310.236.946.36Net Income-$16.55M$153.22M$118.89M$225.56M7 Day Performance-9.55%-1.36%-1.33%-0.10%1 Month Performance-23.24%-6.81%-3.17%2.02%1 Year PerformanceN/A32.27%32.49%27.87% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$2.84-4.7%N/AN/A$10.68M$4.50M-0.24N/AGap DownHigh Trading VolumeRVPHReviva Pharmaceuticals2.6394 of 5 stars$1.27+4.1%$15.50+1,125.3%-71.1%$42.30MN/A0.005VYNEVYNE Therapeutics2.5605 of 5 stars$2.83+0.4%$6.88+142.9%-28.6%$41.74M$420,000.000.0030Analyst ForecastRLYBRallybio2.5438 of 5 stars$1.00+0.6%$9.75+875.0%-59.4%$41.49MN/A0.0040XLOXilio Therapeutics1.9025 of 5 stars$0.90-4.4%$4.00+344.3%-21.6%$39.57MN/A-0.5573ANEBAnebulo Pharmaceuticals2.5152 of 5 stars$1.51-0.7%$8.00+429.8%-30.9%$39.15MN/A0.004Analyst ForecastShort Interest ↓News CoverageGap DownHigh Trading VolumeBRNSBarinthus Biotherapeutics1.6614 of 5 stars$0.99+10.1%$5.83+489.3%-69.1%$39.14M$800,000.00-0.60107Analyst ForecastOSTXOS TherapiesN/A$1.83+6.1%N/AN/A$38.87MN/A0.00N/ALUMOLumos Pharma3.2177 of 5 stars$4.33+0.2%$8.63+99.2%+41.2%$37.45M$2.05M0.0030High Trading VolumeRAPTRAPT Therapeutics4.5983 of 5 stars$1.06-1.4%$9.50+800.5%-92.3%$36.88M$1.53M0.0080FGENFibroGen2.4656 of 5 stars$0.36+4.2%N/A-33.8%$36.75M$147.75M-0.28486Analyst RevisionGap Down Related Companies and Tools Related Companies RVPH Competitors VYNE Competitors RLYB Competitors XLO Competitors ANEB Competitors BRNS Competitors OSTX Competitors LUMO Competitors RAPT Competitors FGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CSCI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
